BioSpace News Archive

Can-Fite BioPharma Ltd today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

Spectral Medical Inc. today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Avicanna Inc. is pleased to announce ANVISA has granted commercialization approval of Ease Labs Pharma (“ Ease Labs ”) pharmaceutical preparation produced in Brazil containing Avicanna’s Aureus branded active pharmaceutical ingredient (“ API ”).

Tome Biosciences, Inc., the programmable genomic integration company, announces the appointment of Daniel Curran, MD, to its Board of Directors.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications.

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced today that the management team will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13th.

MaxCyte, Inc. and Wugen, Inc. announced the signing of a strategic platform license.

MiNK Therapeutics, Inc. announced the publication of a case report in Oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response, highlighting the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors.

IceCure Medical Ltd. (NASDAQ: ICCM) (“IceCure” or the “Company”) today announced the U.S. Food and Drug Administration (“FDA”) has responded affirmatively to the Company’s request for supervisory review (“Appeal”) under 21 CFR 10.75 regarding the FDA’s prior denial of IceCure’s De Novo Classification Request for treating patients with early-stage, low risk breast cancer.